Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 4/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | ICMT | O60725 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20848478 | 0.97 | AR (0.36) | ARKIF11PTGER4CYP2C9SCN9A | |
| SCHEMBL20848743 | 0.96 | AR (0.37) | ARKIF11PTGER4CYP2C9SCN9A | |
| SCHEMBL20848433 | 0.96 | AR (0.37) | ARKIF11PTGER4CYP2C9SCN9A | |
| SCHEMBL20848465 | 0.96 | AR (0.39) | ARKIF11CYP2C9SCN9AELANE | |
| SCHEMBL20848980 | 0.95 | KIF11 (0.33) | ARKIF11PTGER4CYP2C9SCN9A | |
| SCHEMBL22985331 | 0.95 | AR (0.38) | ARKIF11PTGER4AKR1C3AKR1C2 | |
| SCHEMBL20848720 | 0.95 | KIF11 (0.38) | ARKIF11PTGER4CYP2C9SCN9A | |
| SCHEMBL20849072 | 0.94 | PTGER4 (0.32) | ARKIF11PTGER4CYP2C9SCN9A | |
| SCHEMBL20848777 | 0.94 | KIF11 (0.35) | ARKIF11PTGER4CYP2C9SCN9A | |
| SCHEMBL20848466 | 0.94 | KIF11 (0.35) | ARKIF11PTGER4CYP2C9SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10978646-B2 | Organic molecules for use in optoelectronic devices | CYNORA GMBH (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20190097141-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10978646-B2 | Organic molecules for use in optoelectronic devices | OCIAD2, OCIAD1, POU2F1 | AR 3706/4885KIF11 419/4885PTGER4 3716/4885 |
| US-20190097141-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | OCIAD2, OCIAD1, POU2F1 | AR 3706/4885KIF11 419/4885PTGER4 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.